Alex Hoyle
The Christie NHS Foundation Trust(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, Cancer, Lipids, and Metabolism, Cancer Genomics and Diagnostics
Most-Cited Works
- → Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial(2018)1,235 cited
- → Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial(2019)395 cited
- → Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer(2019)201 cited
- → Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer(2021)132 cited
- → Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial(2022)115 cited
- → Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol(2023)90 cited
- → Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)(2022)73 cited
- → Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial(2020)34 cited
- → Accumulation of copy number alterations and clinical progression across advanced prostate cancer(2022)27 cited
- → Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer(2018)24 cited